Public filings / COAG on Yahoo Finance (opens in a new tab)
COAG: insider buying, 13F holders, analyst moves
Hemab Therapeutics Holdings
A summary of public filings about Hemab Therapeutics Holdings. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
5 of our 100 managers hold COAG
Combined reported value $500.8M.
Holders among our 100 managers: 0 in Q3 2023, 5 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| RA Capital | $286.8M | 2.49% | New |
| Deep Track Capital | $132.3M | 1.95% | New |
| Avoro Capital Advisors | $70.7M | 0.64% | New |
| Deerfield Company | $10.1M | 0.10% | New |
| Soros Fund Management | $918K | 0.01% | New |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.